Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 6
1968 4
1969 4
1970 2
1971 2
1972 7
1973 5
1974 5
1975 4
1976 4
1977 2
1978 1
1979 3
1980 1
1981 1
1982 2
1983 3
1984 1
1985 3
1986 29
1987 38
1988 41
1989 44
1990 30
1991 41
1992 49
1993 40
1994 37
1995 35
1996 34
1997 30
1998 30
1999 45
2000 35
2001 51
2002 69
2003 50
2004 67
2005 93
2006 94
2007 90
2008 99
2009 125
2010 149
2011 162
2012 176
2013 148
2014 153
2015 164
2016 134
2017 138
2018 143
2019 104
2020 17
Text availability
Article attribute
Article type
Publication date

Search Results

2,548 results
Results by year
Filters applied: . Clear all
Page 1
Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K, Stankov S, Katanic J. Stankov K, et al. Curr Pharm Des. 2017;23(1):135-169. doi: 10.2174/1381612822666161003160033. Curr Pharm Des. 2017. PMID: 27697023 Review.
Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.
Wesa KM, Cunningham-Rundles S, Klimek VM, Vertosick E, Coleton MI, Yeung KS, Lin H, Nimer S, Cassileth BR. Wesa KM, et al. Cancer Immunol Immunother. 2015 Feb;64(2):237-47. doi: 10.1007/s00262-014-1628-6. Epub 2014 Oct 29. Cancer Immunol Immunother. 2015. PMID: 25351719 Free PMC article. Clinical Trial.
Immunosuppressive therapy for myelodysplastic syndromes.
Dobbelstein C, Ganser A. Dobbelstein C, et al. Curr Pharm Des. 2012;18(22):3184-9. doi: 10.2174/1381612811209023184. Curr Pharm Des. 2012. PMID: 22571697 Review.
Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S, Santini V, Musallam K, Taher A. Temraz S, et al. Crit Rev Oncol Hematol. 2014 Jul;91(1):64-73. doi: 10.1016/j.critrevonc.2014.01.006. Epub 2014 Jan 24. Crit Rev Oncol Hematol. 2014. PMID: 24529413 Review.
2,548 results
Jump to page
Feedback